Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

T Kalincik; V Jokubaitis; G Izquierdo; P Duquette; M Girard; P Grammond; A Lugaresi; C Oreja-Guevara; R Bergamaschi; R Hupperts; F Grandmaison; E Pucci; V Van Pesch; C Boz; G Iuliano; R Fernandez-Bolanos; S Flechter; D Spitaleri; E Cristiano; F Verheul; J Lechner-Scott; MP Amato; JA Cabrera-Gomez; ML Saladino; M Slee; F Moore; O Gray; M Paine; M Barnett; E Havrdova; D Horakova; T Spelman; M Trojano; H Butzkueven

Journal article

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

T Kalincik, V Jokubaitis, G Izquierdo, P Duquette, M Girard, P Grammond, A Lugaresi, C Oreja-Guevara, R Bergamaschi, R Hupperts, F Grandmaison, E Pucci, V Van Pesch, C Boz, G Iuliano, R Fernandez-Bolanos, S Flechter, D Spitaleri, E Cristiano, F Verheul Show all

Multiple Sclerosis | SAGE PUBLICATIONS LTD | Published : 2015

DOI: 10.1177/1352458514559865

Download PDF

Abstract

Background: The results of head-to-head comparisons of injectable immunomodulators (interferon β, glatiramer acetate) have been inconclusive and a comprehensive analysis of their effectiveness is needed. Objective: We aimed to compare, in a real-world setting, relapse and disability outcomes among patientswith multiple sclerosis (MS) treated with injectable immunomodulators. Methods: Pairwise analysis of the international MSBase registry data was conducted using propensityscore matching. The four injectable immunomodulators were compared in six head-to-head analyses of relapse and disability outcomes using paired mixed models or frailty proportional hazards models adjusted for magnetic reson..

View full abstract

University of Melbourne Researchers

Tomas Kalincik Author

Timothy Spelman Author

Related Projects (5)

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

SELECTING OPTIMAL TREATMENT FOR PATIENTS WITH MULTIPLE SCLEROSIS

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

Grants

Awarded by Novartis

Funding Acknowledgements

The work was supported by the Multiple Sclerosis Research Australia Postdoctoral Fellowship [11-054] and NHMRC Early Career Award (Clinical) to TK [1071124], NHMRC Career Development Award (Clinical) to HB [628856], NHMRC Project Grant [1032484], NHMRC Centre for Research Excellence [1001216] and the MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer Schering, Sanofi-Aventis and BioCSL. The study was conducted separately and apart from the guidance of the sponsors. TK had full access to all the data and takes responsibility for integrity of the data and accuracy of the data analysis.